{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:41:04Z","timestamp":1793677264187,"version":"4.5.1"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Cirrhosis is a significant global health burden, with serious liver-related complications leading to high morbidity and mortality. Effective therapeutic options to mitigate these complications remain limited. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, primarily used in diabetes and heart failure management, may offer additional liver-related benefits.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association between SGLT-2 inhibitor use and the risk of serious liver events in patients with cirrhosis receiving furosemide and spironolactone.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used data from over 120 health care organizations within the TriNetX platform. Adult patients with cirrhosis who were receiving furosemide and spironolactone from January 2013 to July 2021 were included. Patients who were receiving SGLT-2 inhibitors plus furosemide and spironolactone were matched with a control group of patients who were receiving furosemide and spironolactone alone according to age, demographics, and comorbidities using 1:1 propensity matching. Each patient was followed up for 3 years; follow-up ended on July 11, 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Use of SGLT-2 inhibitors.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary outcome was a composite of serious liver events defined as incidence of ascites, variceal development, hyponatremia, or all-cause mortality. Secondary outcomes included incidence of variceal bleeding, paracentesis, spontaneous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, hepatocellular carcinoma, hypoglycemia, and all-cause hospitalizations. Continuous variables were compared using an independent-samples\n t<\/jats:italic>\n test; categorical variables were compared using the Pearson \u03c7\n 2<\/jats:sup>\n test.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 10\u202f660 propensity-matched patients (mean [SD] age, 63.8 [10.7] years; 57.8% male), those receiving SGLT-2 inhibitors had a lower incidence of serious liver events compared with control patients (hazard ratio [HR], 0.68 [95% CI, 0.66-0.71];\n P<\/jats:italic>\n &amp;lt; .001). Secondary outcomes included hepatorenal syndrome (HR, 0.47 [95% CI, 0.40-0.56]), spontaneous bacterial peritonitis (HR, 0.55 [95% CI, 0.46-0.65]), paracentesis (HR, 0.54 [95% CI, 0.50-0.60]), variceal bleeding (HR, 0.79 [95% CI, 0.73-0.84]), hypoglycemia (HR, 0.75 [95% CI, 0.62-0.91]), and all-cause hospitalizations (HR, 0.67 [95% CI, 0.63-0.71]), all of which were associated with a reduced risk among those in the SGLT-2 inhibitors group.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of adults with cirrhosis who were receiving diuretic therapy, the findings suggest that SGLT-2 inhibitor use was associated with a lower incidence of serious liver events. These findings further suggest a potential role for SGLT-2 inhibitors in cirrhosis management.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.18470","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T11:30:40Z","timestamp":1751023840000},"page":"e2518470","source":"Crossref","is-referenced-by-count":30,"title":["Sodium-Glucose Cotransporter 2 Inhibitors and Serious Liver Events in Patients With Cirrhosis"],"prefix":"10.1001","volume":"8","author":[{"given":"Mohamad-Noor","family":"Abu-Hammour","sequence":"first","affiliation":[{"name":"Department of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Abdel-Razeq","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravinthan","family":"Vignarajah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raneem","family":"Khedraki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, Ohio"},{"name":"Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar T.","family":"Sims","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, Ohio"},{"name":"Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio"},{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishanthi","family":"Vigneswaramoorthy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The State University of New York Upstate Medical University, Syracuse"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian J.","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, Ohio"},{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"issue":"2","key":"zoi250576r1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: an update.","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"zoi250576r2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review.","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"zoi250576r3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.800490","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism.","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"16","key":"zoi250576r4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016270","article-title":"Molecular, cellular, and clinical evidence that sodium-glucose cotransporter 2 inhibitors act as neurohormonal antagonists when used for the treatment of chronic heart failure.","volume":"9","author":"Packer","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"zoi250576r5","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"zoi250576r6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/gut.2008.176495","article-title":"Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.","volume":"59","author":"Angeli","year":"2010","journal-title":"Gut"},{"issue":"2","key":"zoi250576r7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0168-8278(03)00188-0","article-title":"Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. a randomized comparative study of efficacy and safety.","volume":"39","author":"Santos","year":"2003","journal-title":"J Hepatol"},{"issue":"2","key":"zoi250576r8","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases.","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"zoi250576r10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"4","key":"zoi250576r11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores.","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"zoi250576r12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi250576r13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jama.2012.96867","article-title":"Prespecified falsification end points: can they validate true observational associations?","volume":"309","author":"Prasad","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"zoi250576r14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s12876-023-03085-8","article-title":"Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.","volume":"23","author":"Huynh","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"12","key":"zoi250576r15","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","article-title":"Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.","volume":"73","author":"Mao","year":"2024","journal-title":"Gut"},{"issue":"4","key":"zoi250576r16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/ckj\/sfab266","article-title":"Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor.","volume":"15","author":"Miyamoto","year":"2021","journal-title":"Clin Kidney J"},{"issue":"9","key":"zoi250576r17","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1136\/gut.2006.102764","article-title":"MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation.","volume":"56","author":"Londo\u00f1o","year":"2007","journal-title":"Gut"},{"issue":"6","key":"zoi250576r18","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/ajg.2009.293","article-title":"Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis.","volume":"104","author":"Guevara","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"zoi250576r19","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1681\/ASN.2022050623","article-title":"Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial.","volume":"34","author":"Refardt","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"zoi250576r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14740\/jem632","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes: a chart-based analysis.","volume":"10","author":"Katsuyama","year":"2020","journal-title":"J Endocrinol Metab"},{"issue":"1-3","key":"zoi250576r21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"zoi250576r22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"zoi250576r23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1124\/jpet.122.001289","article-title":"Sodium-glucose cotransporter-2 inhibition exacerbates hepatic encephalopathy in biliary cirrhotic rats.","volume":"383","author":"Hsu","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"zoi250576r24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.510300124","article-title":"Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.","volume":"30","author":"Ba\u00f1ares","year":"1999","journal-title":"Hepatology"},{"key":"zoi250576r9","unstructured":"TriNetX. Accessed August 19, 2024. https:\/\/trinetx.com\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835700\/abuhammour_2025_oi_250576_1750871450.83023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T11:30:43Z","timestamp":1751023843000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.18470","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}